Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cybin ( (TSE:CYBN) ) has shared an update.
On December 30, 2025, Cybin Inc. filed a Form 6-K with the U.S. Securities and Exchange Commission announcing that it has entered into an equity distribution agreement with Cantor Fitzgerald Canada Corporation and Cantor Fitzgerald & Co., allowing the company to issue and sell up to US$100 million of its common shares from time to time through at-the-market and other permitted sales methods. The arrangement, which sets a 3% placement fee for the agents and permits flexible, on-demand share issuances within board-authorized limits, expands Cybin’s capacity to raise growth capital in both U.S. and Canadian marketplaces, potentially providing ongoing funding for its operations and strategic initiatives while diluting existing shareholders as new equity is sold into the market.
The most recent analyst rating on (TSE:CYBN) stock is a Hold with a C$0.13 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Spark’s Take on TSE:CYBN Stock
According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Neutral.
The score is held down primarily by weak financial performance (no revenue, widening losses, and significant cash burn). Offsetting this somewhat are constructive earnings-call updates (financing runway into 2027 and advancing late-stage/near-term clinical milestones) and positive corporate visibility catalysts (Nasdaq move/rebrand), while technical signals and valuation metrics provide limited support.
To see Spark’s full report on TSE:CYBN stock, click here.
More about Cybin
Cybin Inc. is a Toronto-based foreign private issuer listed in the United States that operates in the life sciences sector, focusing on psychedelic-based therapeutics and related intellectual property. The company accesses U.S. and Canadian capital markets via SEC and Canadian securities filings, using equity issuance programs to help fund its clinical development and commercialization efforts.
Technical Sentiment Signal: Hold
Current Market Cap: C$1.92M
Find detailed analytics on CYBN stock on TipRanks’ Stock Analysis page.